Entasis Therapeutics Holdings Inc. (ETTX) will issue more than 4.4 million shares between $16 and $18 Wednesday on the Nasdaq. Entasis spun off from AstraZeneca plc (AZN) in 2015 to treat multidrug-resistant infections.
Arvinas Holding Company, LLC (NARVN) will issue nearly 6.7 million shares between $14 and $16 Thursday on the Nasdaq. Based in New England, the biotech company leverages proprietary protein technology in its oncological and neurological therapies.
RA Medical Systems, Inc. (RMED) will issue more than 3.3 million shares between $14 and $16 Thursday on the New York Stock Exchange. Since 2002, the medtech company has developed and commercialized laser tools to treat vascular and dermatological diseases.
Sutro Biopharma Inc (STRO) will issue 5 million shares between $14 and $16 Thursday on the Nasdaq. Based in San Francisco, Sutro develops and manufactures therapies in oncological and autoimmune indications.
Urovant Sciences Ltd. (UROV) will issue 10 million shares between $14 and $16 Thursday on the Nasdaq. The urology-focused biotech develops candidates for overactive bladder and irritable bowel syndrome.
Gritstone Oncology, Inc. (GRTS) will issue more than 6.07 million shares between $13 and $15 Friday on the Nasdaq. Headquartered in California, the oncology-focused biotech develops immunotherapy products for solid tumors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.